NCT07141329
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
StatusEnrolling by Invitation
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 4 words Show 4 more changesShow less
- Trial status changed: Recruiting → Enrolling by Invitation
- Trial sites expanded: 1 → 8 locations
- Secondary endpoints revised (4)
- Study description expanded, about 12 words
- Notable Phase: Phase 3 to Phase 2
- Study description shortened, about 6 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of treatment-emergent adverse events
Timeframe: Week 1-Week 52
Secondary (4)
Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the 1-year SPN-817 Treatment Period
Proportion of participants experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Proportion of participants experiencing seizure freedom
Percentage of seizure-free days over the 1-year SPN-817 Treatment Period
Arms and interventions
SPN-817Experimental
SPN-817, bid
Drugs: SPN-817
Sites
8 sites in 2 countries
United States 7, Australia 1